1. Tumor immunology

2. Content IMMUNOLOGICAL SURVEILLANCE TUMOR ANTIGENS
EFFECTOR MECHANISMS IN ANTI-TUMOR IMMUNITY
MECHANISMS OF EVASION OF THE IMMUNE SYSTEM BY TUMORS
TUMOR IMMUNOTHERAPY

6. Immunosurveillance
Physiological function of the immune system to recognize and destroy malignantly transformed cells before they grow into tumors, or to kill tumors after they are formed

7. Tumor antigens Tumor-specific antigens (TSA)
Antigens expressed on tumor cells but not on normal cells
Tumor-associated antigens (TAA)
Antigens expressed concurently on normal cells

8. Figure 14-12

9. Figure 14-12

10. Figure 14-13

12. Effector mechanisms in anti-tumor immunity
T lymphocytes NK cells Antibodies Macrophages

16. Effector mechanisms in anti-tumor immunity
T lymphocytes NK cells Antibodies Macrophages

17. Figure 1-6

19. Figure 9-34 part 1 of 2

20. Figure 9-34 part 2 of 2

21. Effector mechanisms in anti-tumor immunity
T lymphocytes NK cells Antibodies Macrophages

24. Effector mechanisms in anti-tumor immunity
T lymphocytes NK cells Antibodies Macrophages

28. Mechanisms of evasion of the immune response by tumors

29. IMPORTANT ISSUES IN DESIGNING EFFECTIVE CANCER VACCINE
Too less good things for initiation of antitumor
immune response
Failure to produce and/or present antigen
Failure to activate T cells
Too many bad things for maintenance of an effective
antitumor immune response
Immunosuppresive cytokines
Induction of immunoprivileges
Induction of regulatory cells

31. Figure part 1 of 2

32. Figure part 2 of 2

33. Tumor immunotherapy Nonspecific Specific Passive Active Vaccination
Monoclonal Abs
adoptive (LAK, TIL)
Active
Vaccination

34. Figure 14-17

35. IMPORTANT ISSUES IN DESIGNING EFFECTIVE CANCER VACCINE
To identify potent tumor rejection antigens
To stimulate an effective antitumor immune
response
To avoid autoimmune pathology